Development and Evaluation of a Combination Formulation of Losartan Potassium as a Sustained- Release Component and Hydrochlorothiazide as an Immediate-Release Component

According to the Prospective Studies Collaboration, lowering blood pressure can significantly lower cardiovascular risk, cardiovascular mortality, and all-cause mortality.When baseline blood pressure is high, this risk reduction is steeper in younger people than in older subjects.Reducing both systolic and diastolic blood pressure was found to prevent cardiovascular events in a meta-analysis of 61 studies with more than a million hypertensive patients and 12.7 million years of follow-up (Turnbull et al., 2005).The Box-Behnken design was effective in formulating microbeads of losartan potassium.The analysis of variance (ANOVA) revealed that the microbeads formulations were significantly affected by the independent variables.The interaction between two variables, namely, the amount of Gellan gum, Chitosan and Calcium chloride, had a significant effect on the properties of the microbeads.The microbeads with the highest encapsulation efficiency were obtained when the amount of Gellan gum was 100mg, Chitosan 40mg and 2% Calcium chloride.The optimized formulation of microbeads had a mean particle size of 375.65nm and a spherical shape with good flowability.These results suggest that the Box-Behnken design is an effective method for formulating losartan potassium microbeads.Further Hydrochlorothiazide granules were prepared and evaluated, the formulation of immediate release granules of hydrochlorothiazide is a promising approach to improve the bioavailability of the drug and reduce its side effects.Further research and